NCT02978859 - Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

December 20, 2021

Conditions

LiposarcomaMetastatic Liposarcoma

Interventions

DRUG

MGCD516

Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.

Trial Locations (3)

10032

Columbia University Irving Medical Center, New York

63130

Washington University, St Louis

02114-2696

Massachussetts General Hospital, Boston